In vitro phenotypic susceptibility of HIV-2 clinical isolates to CCR5 inhibitors

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 1, 2012, Pages 137-139

  Visseaux, Benoit ^a   Charpentier, Charlotte ^a   Hurtado Nedelec, Margarita ^b   Storto, Alexandre ^a   Antoine, Romain ^a   Peytavin, Gilles ^b   Damond, Florence ^a   Matheron, Sophie ^b   Brun Vézinet, Françoise ^a   Descamps, Diane ^a  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b BICHAT HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MARAVIROC;

ANTIVIRAL SUSCEPTIBILITY; ARTICLE; CONCENTRATION RESPONSE; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; VIRAL TROPISM; VIRUS ISOLATION; VIRUS STRAIN;

ANTI-HIV AGENTS; CELLS, CULTURED; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-2; HUMANS; INHIBITORY CONCENTRATION 50; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; MALE; MODELS, BIOLOGICAL; PHYTOHEMAGGLUTININS; RECEPTORS, CCR5; RECEPTORS, CXCR4; SPECIES SPECIFICITY; TRIAZOLES; VIRUS REPLICATION;

EID: 84455169994     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05313-11     Document Type: Article

References (22)

1. Armstrong-James D, et al. 2010. Clinical outcome in resistant HIV-2 infection treated with raltegravir and maraviroc. Antiviral Res. 86: 224-226.
2. Blaak H, et al. 2005. CCR5, GPR15, and CXCR6 are major coreceptors of human immunodeficiency virus type 2 variants isolated from individuals with and without plasma viremia. J. Virol. 79:1686-1700. (Pubitemid 40459115)
3. Brunet S, et al. 2008. Surveillance de l'infection à VIH-sida en France, 2007. Bull. Epid. Hebdo. 53:434-442.
4. Brun-Vézinet F, et al. 1992. HIV-1 sensitivity to zidovudine: a consensus culture technique validated by genotypic analysis of the reverse transcriptase. J. Virol. Methods 37:177-188.
5. Calado M, et al. 2010. Coreceptor usage by HIV-1 and HIV-2 primary isolates: the relevance of CCR8 chemokine receptor as an alternative coreceptor. Virology 408:174-182.
6. Damond F, et al. 2005. Improved sensitivity of human immunodeficiency virus type 2 subtype B plasma viral load assay. J. Clin. Microbiol. 43:4234-4236. (Pubitemid 41129736)
7. Dorr P, et al. 2005. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 49:4721-4732. (Pubitemid 41552605)
8. Guillon C, et al. 1998. Coreceptor usage of human immunodeficiency virus type 2 primary isolates and biological clones is broad and does not correlate with their syncytium-inducing capacities. J. Virol. 72: 6260-6263. (Pubitemid 28283428)
9. McKnight A, et al. 1998. A broad range of chemokine receptors are used by primary isolates of human immunodeficiency virus type 2 as coreceptors with CD4. J. Virol. 72:4065-4071. (Pubitemid 28188711)
10. Mörner A, et al. 1999. Primary human immunodeficiency virus type 2 (HIV-2) isolates, like HIV-1 isolates, frequently use CCR5 but show promiscuity in coreceptor usage. J. Virol. 73:2343-2349. (Pubitemid 29098139)
11. Mörner A, et al. 2002. CCR5 or CXCR4 is required for efficient infection of peripheral blood mononuclear cells by promiscuous human immunodeficiency virus type 2 primary isolates. AIDS Res. Hum. Retroviruses 18:193-200. (Pubitemid 34161238)
12. Owen SM, et al. 1998. Genetically divergent strains of human immunodeficiency virus type 2 use multiple coreceptors for viral entry. J. Virol. 72:5425-5432. (Pubitemid 28283323)
13. Poveda E, Briz V, Soriano V. 2005. Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev. 7:139-147. (Pubitemid 41671913)
14. Ren J, et al. 2002. Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc. Natl. Acad. Sci. U. S. A. 99:14410-14415. (Pubitemid 35257685)
15. Roquebert B, et al. 2008. HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J. Antimicrob. Chemother. 62: 914-920.
16. Stegmann S, et al. 2010. Foscarnet as salvage therapy in HIV-2-infected patient with antiretroviral treatment failure. J. Clin. Virol. 47:79-81.
17. Valadas E, França L, Sousa S, Antunes F. 2009. 20 years of HIV-2 infection in Portugal: trends and changes in epidemiology. Clin. Infect. Dis. 48:1166-1167.
18. Visseaux B, et al. Molecular determinants of HIV-2 R5-X4 tropism in the V3 loop: development of a new genotypic tool. J. Infect. Dis., in press.
19. Westby M, et al. 2007. Reduced maximal inhibition in phenotypic susceptibility assays indicates that viral strains resistant to the CCR5 antagonist maraviroc utilize inhibitor-bound receptor for entry. J. Virol. 81: 2359-2371.
20. Willey S, et al. 2005. Inhibition of CCR5-mediated infection by diverse R5 and R5X4 HIV and SIV isolates using novel small molecule inhibitors of CCR5: effects of viral diversity, target cell and receptor density. Antiviral Res. 68:96-108. (Pubitemid 41565524)
21. Witvrouw M, et al. 2004. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir. Ther. 9:57-65. (Pubitemid 38313948)
22. Zhang Y, et al. 2000. Use of inhibitors to evaluate coreceptor usage by simian and simian/human immunodeficiency viruses and human immunodeficiency virus type 2 in primary cells. J. Virol. 74:6893-6910. (Pubitemid 30470673)